Atlas Trials

Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Clinical trial NCT06025214 · UNKNOWN

Trial details

NCT number
NCT06025214
Sponsor
Respirent Pharmaceuticals Co Ltd.
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Bioequivalence
Start date
2023-08-22
Primary completion
2023-09-22
Enrollment
34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.